Profitability
Weight: 25%
C+
60
- 5yr Avg ROIC 17.1%
- Operating Margin Trend -4.50 pp/yr
VRTX
Vertex Pharmaceuticals Incorporated
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
Capital Efficiency
Weight: 15%
A-
80
- 5yr Avg ROE 17.1%
- 5yr Share-Count CAGR -0.4%
Growth Quality
Weight: 25%
A-
85
- 5yr Revenue CAGR 14.2%
- 5yr EPS CAGR 8.3%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
A+
97
- 5yr FCF Margin 25.7%
- 5yr FCF/NI Conversion 0.98x
Balance Sheet
Weight: 10%
A+
99
- Net Debt / EBITDA -0.56x
- Interest Coverage (EBIT/Int) 350.11x
- Altman Z-Score 12.73
Stability
Weight: 5%
C
51
- EPS Volatility (σ/μ) 0.52
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 4
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 4 trimmed.
- Holders
- 4
- Avg Δ position
- -45.5%
- New buys
- 0
- Full exits
- 0